Arvinas to Unveil Phase 1 Biomarker Data for Parkinson’s Drug…

Event summary

Arvinas will present late-breaking biomarker data from a Phase 1 trial of ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders.
ARV-102 is designed to cross the blood-brain barrier and target LRRK2, a protein linked to Parkinson’s disease and progressive supranuclear palsy (PSP).
The presentations will include both oral and e-poster sessions on October 7, 2026, during the MDS Congress in Seoul, Korea.
Arvinas has previously developed the first FDA-approved PROTAC in collaboration with Pfizer, which was outlicensed to Rigel Pharmaceuticals.

The big picture

Arvinas’ presentation of Phase 1 biomarker data for ARV-102 comes at a critical juncture in the development of targeted protein degradation therapies for Parkinson’s disease. The company’s PROTAC platform has already demonstrated success with the FDA approval of its first PROTAC, highlighting its potential to revolutionize the treatment of complex neurological disorders. The upcoming data could position Arvinas as a key player in the neurodegenerative disease space, particularly if the results support further clinical advancement.

What we're watching

Clinical Efficacy: How the biomarker data from ARV-102’s Phase 1 trial will influence the perception of its potential as a treatment for Parkinson’s disease.
Regulatory Pathway: Whether the positive biomarker data will accelerate ARV-102’s path to further clinical trials or regulatory approval.
Competitive Positioning: The pace at which Arvinas can differentiate ARV-102 in the crowded landscape of neurodegenerative disease therapies.